Comparative Effectiveness of Vonoprazan Dosing Strategies in Bismuth-Based Quadruple Therapy for Helicobacter pylori Eradication: A Prospective Non-inferiority Cohort Study
Open Access
- 13 February 2026
- journal article
- Published by AVES YAYINCILIK A.Ş. in Turkish Journal of Gastroenterology
- Vol. 37 (5) , 583-589
Abstract
Background/Aims: Vonoprazan 20 mg twice daily is effective for Helicobacter pylori (H.pylori) eradication, but studies on the efficacy of 20 mg once daily are limited. The efficacy, tolerability, and cost-effectiveness of bismuth-based quadruple therapy with vonoprazan 20 mg once daily were evaluated for H. pylori eradication. Materials and Methods: A prospective cohort study was conducted at TaiZhou Hospital of Zhejiang Province between January and September 2024. Participants were divided into 2 groups: low-dose vonoprazan (QD, 20 mg once daily) and standard-dose vonoprazan (BID, 20 mg twice daily). The remaining drugs (colloidal bismuth pectin, clarithromycin, and amoxicillin) were the same for both groups, with a treatment duration of 14 days. Urea breath tests were performed 6-8 weeks post treatment. Results: In the intention-to-treat analysis, eradication rates were 89.2% (91/102) in the QD group and 88.9% (88/99) in the BID group, with no significant difference (P = .941). In the per-protocol (PP) analysis, eradication rates were 92.2% (83/90) in the QD group and 95.2% (79/83) in the BID group, also without a significant difference (P = .426). The incidence of adverse events was 8.9% in the QD group and 12.0% in the BID group (P = .497), respectively. The cost-effectiveness ratios were 2.59 for the QD group and 3.96 for the BID group in the PP analysis, respectively. Conclusion: Vonoprazan 20 mg once daily showed comparable efficacy to twice-daily dosing as part of a bismuth-based quadruple regimen for H. pylori eradication, with better cost-effectiveness, making it a promising option, especially in resource-limited settings. Cite this article as: Yan L, Lin R, Zhang Y, et al. Comparative effectiveness of vonoprazan dosing strategies in bismuth-based quadruple therapy for Helicobacter pylori eradication: A prospective non-inferiority cohort study. Turk J Gastroenterol. Published online February 13, 2026. doi: 10.5152/tjg.2026.25645.Keywords
This publication has 26 references indexed in Scilit:
- Vonoprazan: A Review in Helicobacter pylori InfectionDrugs, 2024
- Global Prevalence of Helicobacter pylori Infection and Incidence of Gastric Cancer Between 1980 and 2022Gastroenterology, 2024
- The Efficacy and Safety of Regimens for Helicobacter pylori Eradication Treatment in ChinaJournal of Clinical Gastroenterology, 2023
- Comparative Effectiveness of Multiple Different First-Line Treatment Regimens for Helicobacter pylori Infection: A Network Meta-analysisGastroenterology, 2021
- Gastric cancerThe Lancet, 2020
- Cost-Effectiveness Analysis of Helicobacter pylori Eradication Therapy for Prevention of Gastric Cancer: A Markov ModelDigestive Diseases and Sciences, 2019
- Helicobacter pylori Therapy for the Prevention of Metachronous Gastric CancerNew England Journal of Medicine, 2018
- Update on the Use of Vonoprazan: A Competitive Acid BlockerGastroenterology, 2018
- New concepts of resistance in the treatment of Helicobacter pylori infectionsNature Clinical Practice Gastroenterology & Hepatology, 2008
- Clarithromycin vs. furazolidone in quadruple therapy regimens for the treatment of Helicobacter pylori in a population with a high metronidazole resistance rateAlimentary Pharmacology & Therapeutics, 2001